Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
Efforts by companies and policymakers to promote sustainable aviation fuel (SAF) are hastening a future of greener air travel, BIO President and CEO Dr. […]
Sustainable aviaton fuel makes air travel greener, BIO CEO writes Read More »
The convoluted, confusing, and opaque system for pricing drugs is distorting the market—and limiting access to drugs for the sickest patients. This is the
I am BIO Podcast: Dysfunctional drug market means sickest pay more Read More »
Along with funding pandemic preparedness, “U.S. policymakers and lawmakers need to broaden their vision to include preparing for human-generated chemical, biological, radiological, and nuclear
BIO’s View: Russian aggression demands more investment in medical countermeasures Read More »
Envionmental, Social and corporate Governance (ESG) investors should take into account all the good that biotechnolgy is doing, BIO President and CEO Dr. Michelle
BIO’s CEO in Forbes: Biotech offers value for ESG investors Read More »
In her latest I am BIO Podcast, BIO President and CEO Dr. Michelle McMurry-Heath speaks with three guests who are fighting to bend the
I am BIO Podcast: Hope for Alzheimer’s Read More »
The United States Trade Representative (USTR) Special 301 Report on Intellectual Property and Protection and Enforcement, released last week, is encouraging for calling out
USTR puts China on Priority Watch List, but still supports waiving IP protection Read More »
A broad coalition of 77 companies and associations that are stakeholders in the aviation industry—including the Biotechnology Innovation Organization (BIO) and its member companies,
BIO, business community call for SAF tax incentives Read More »
China’s proposed rules on human genetics resource (HGR) would significantly restrict how foreign entities are able to access and use Chinese HGR for global
BIO: China’s human genetic resources regulations could threaten global R&D Read More »
When the Biotechnology Innovation Organization (BIO) says they bring people together, they mean it. The last time the BIO International Convention was held in
BIO International Convention makes partnering a priority Read More »
Everyone’s talking about pharmacy benefit managers (PBMs)—including the Federal Trade Commission (FTC)—but what exactly are PBMs and why do they matter in the context
What are PBMs, anyway? Read More »
